Cancer and Hematology

Research Focus Dermatology

The ultimate goal of the research is to increase the understanding of the underlying mechanisms of skin diseases, in order to facilitate the development of more specific treatments and clinical care.

Bigpicture

The 6-year, €70 million project called BIGPICTURE, will herald a new era in pathology and take AI development in pathology to the next level: we will develop the world’s biggest repository for sharing of pathology data.

Nucleic Acids Technologies Lab

The Nucleic Acids Technologies Lab explores the use of nucleic acids as biorecognition molecules to develop highly specific and sensitive systems, with various detection modalities.

Leukemia and blood stem cells

Regulation of survival and differentiation of hematopoietic stem cells and leukemia-initiating cells.

Endocrine tumors

Molecular genetic analysis of endocrine tumors (thyroid, parathyroid, adrenal, neuroendocrine): pathogenesis and development of metastases.

Genetics and Toxicology in Cancer Chemotherapy and Forensic Sciences

The aim of our research is to identify, validate and implement genetic markers or other biomarkers to predict drug metabolism or drug effects.

Skin cancer prevention in primary care

Studies to improve survival and quality of life among women with gynecological cancer

We want to improve the treatment for patients with gynecological cancer with the aim of prolonging survival without causing short- and long-term side-effects affecting daily life activities.

Forum Scientium Graduate School

Graduate school Forum Scientium, a bridge between medicine, natural sciences and engineering, stimulates creativity and a common use of ideas, knowledge, and equipment.

Oncopharmacology

Our research is within the field of Drug research and Onco-pharmacology. Our aim is to identify drugs with new mechanisms of action, and try to develop drug candidates for clinical use.

Importance of pharmacogenetics for individualising chemotherapy

In addition to cellular studies, we study TPMT and the various genetic variants using recombinant protein. We use biophyscial techniques to study the difference in protein stability and drug affinity between TPMT and other genetic varieties.

Cancer researcher Linda Bojmar leads a unique study in humans

What’s it like to lead a research group, spend half your life on an airplane across the Atlantic, while making sure that family life runs smoothly? This is the reality facing Linda Bojmar every day, now back in Linköping to work on a unique study.

Possible biological explanation for increased cancer risk in dense breasts

The risk of developing breast cancer is higher in what are known as dense breasts. Researchers at LiU have now shown that there are major biological differences between dense breasts and nondense breasts.

SEK 6.8 million for research into pancreatic cancer

Linda Bojmar is to research the role of the liver in the processes whereby pancreatic cancer can spread secondary tumours to the liver. She has received 6.8 million Swedish kronor for a research project from the Swedish Society for Medical Research.

Photon-counting helps both patients and researchers

One of the world’s first photon-counting computed tomography imaging devices has been installed in the Center for Medical Image Science and Visualization (CMIV) at Linköping University Hospital.

Existing drug opens new possibilities for treating child leukemia

A new study has shown that the tumour-inhibiting gene TET2 is silenced in a large fraction of cases of acute lymphoblastic leukemia (ALL) in children. The scientists show that the gene can be reactivated by an existing drug.

SEK 10 million for research in children's medicine

The Joanna Cocozza Foundation has announced the recipients of research grants for 2020. Funding has been awarded in the form of establishment and consolidation grants, support for visiting researchers, and a further seven project grants.

Predicting the risk of severe side effects of cancer treatment

Some patients experience life-threatening side effects during cancer treatment. Researchers at LiU have developed a model that can predict which patients have a high probability of side effects.

Small particles in the blood can reveal early-stage cancer

Small particles released by cancer cells into the blood contain specific proteins. In a new international study, the investigators have been able to match specific EVP profiles with various types of cancer, including early stages.

The right dose to the right person

Malin Lindqvist Appell develops tools to tailor the treatment of leukaemia and inflammatory bowel disease. Serious adverse drug reactions can now be avoided using a blood sample to determine who can take a lower dose of a thiopurine drug.

Digital twins – an aid to tailor medication to individual patients

Advanced computer models of diseases can be used to improve diagnosis and treatment. The goal is to develop the models to “digital twins” of individual patients. Those twins may help to computationally identify and try the best medication.

Major flaw discovered in widely used method

An error in one of the most widely used methods in epigenetics research can cause misleading results. This may have major significance in the research field. The findings by researchers at LiU are published in Nature Methods.

Promising first step towards new cancer treatment

Small molecules that interfere with the cell's protection against harmful oxygen compounds can kill cancer cells. The new study, by a multicentre team with reseachers from Karolinska Institutet and LiU, is published in Science Translational Medicine.

Doctoral studies – slightly risky but lots of fun

Secure employment certainly has its benefits. But Katriann Arja chose a slightly riskier route: a research degree.

Blood platelets disinfected to death

If blood becomes too thin, a transfusion with blood platelets may be necessary – but potential pathogenic agents must first be rendered harmless.The substances used for this unfortunately also destroy the blood platelets themselves.

New concept for treatment of cancer

A completely new method for treating cancer has been developed by a Swedish research team, under the leadership of Karolinska Institutet and Science for Life Laboratory. The concept is to be presented in the prestigious journal, Nature.

Toxic chemical linked to cancer and heart disease

More than 40 years after a major spill of PCBs, these can still be traced in the bloodstream of exposed people. Particularly high levels of PCBs have been measured in the lipoproteins of people with cancer and cardiovascular disease.